
Morepen Laboratories Q3 FY22 Earnings Call Analysis
Revenue, margin, capex, fundraise and order book outlook from management commentary.
Management growth scorecard
Revenue
Category 2
Margin
Category 3
Fundraise
Yes
Order
N/A
Capex
Yes
2 of 4 growth signals are positive.
Full analysisRevenue guidance
Category 2- The company has maintained a historical CAGR revenue growth of around 25%, currently achieving 30% growth, and is comfortable sustaining 20-30% CAGR going forward.
- Medical devices segment has grown at a CAGR of approximately 41-46% and is expected to continue strong growth with capacity expansions and wider market reach.
- Online sales have surged significantly, with a 441% increase quarter-on-quarter and 30-40% ongoing quarterly growth, indicating strong future momentum.
- Expansion in API production capacity planned from 300 KL to 1000 KL over 3 years to meet growing demand, enabling exponential sales growth through new molecule opportunities.
- New product launches (e.g., US FDA-approved Fexofenadine, Dapagliflozin, fertility range) and increased marketing investments are expected to further drive topline growth.
- The forthcoming authorization for Sputnik vaccine production could open a substantial new revenue stream, though dependent on bulk supply availability.
- Strategic focus on global markets, particularly in neighboring countries and beyond, to capture larger market share.
See what Morepen Laboratories management said on margin guidance — free account, 30 seconds.
Fundraise plans
Yes- The company is open to raising capital but has not started any formal process yet (Page 13).
- Informal discussions are ongoing with associates and advisors regarding fundraising (Page 13).
- There is openness to bringing in equity players either in the medical devices subsidiary or in the parent company (Page 22).
- No specific timelines or amounts have been provided; plans will be announced once finalized (Page 13, 22).
- The company is also open to partnerships, M&A, and inviting new investors to the board to support growth (Page 22).
- Previously, inability to access the market limited fundraising, but the current situation is described as a "historical moment" allowing for capital infusion (Page 22).
- No mention of new debt raising; focus appears to be more on equity capital raising.
See what Morepen Laboratories management said on order book — free account, 30 seconds.
Capex plans
Yes- Capex of around ₹22 Crores planned for the year, including ₹12 Crores spent and ₹5 Crores work in progress (Page 20).
- ₹45 Crores investment in medical devices over nine months, showing significant focus on this segment (Page 20).
- Expansion planned to increase capacity from 300 KL to 1000 KL over three years for API segment, requiring additional capex (Page 19).
- Setting up plant for ANDA and ABS, but filing is 2 years away due to validation process (Page 21).
- Demerger of medical devices business into a separate 100% owned subsidiary to attract better capital, customers, and talent (Page 14).
- Increased R&D spending (up 58%) primarily in API and finished dosages, with plans to ramp up further as topline grows (Page 12).
- Heavy investments in meters and marketing for medical devices, including celebrity endorsements, to expand market reach (Pages 7, 11).
- Open to bringing equity investors or partners via M&A to support growth, including in medical devices or parent company (Page 22).
Track Morepen Laboratories — get its next earnings analysis in your feed
How does Morepen Laboratories rank vs peers in Pharmaceuticals & Biotechnology?
Pro featureHow does Morepen Laboratories rank in Pharmaceuticals & Biotechnology?
Compare Morepen Laboratories against every Pharmaceuticals & Biotechnology company (Q3 FY22) on revenue, margins and earnings-call signals.
Continue your research
What Morepen Laboratories's management said in earlier quarters
Others in Pharmaceuticals & Biotechnology this season
- Lasa Supergeneri (Q2 FY27)
306.11 Lakhs in Q2 Sept 30, 2025 (over 99% decline YoY). Key results statement takeaways from Lasa Supergenerics Ltd's Q2 FY27 results statement — and how it ra
- Themis Medicare (Q2 FY27)
Q2 FY27 net revenue: ₹89.74 crore, up 15.1% year-on-year from ₹77.99 crore in Q2 FY26 (Page 8). Key investor presentation takeaways from Themis Medicare Ltd's Q
- Panacea Biotec (Q2 FY27)
September 30, 2026: ₹18,967 Lakh . Key results statement takeaways from Panacea Biotec Ltd's Q2 FY27 results statement — and how it ranks against sector peers.
- Biofil Chemicals (Q2 FY27)
Quarterly Revenue (Q2 ended 30/09/2026):** ₹166.87 Lakhs (Pharma Unit), ₹0.00 Lakhs (Chemicals Division); Total Gross Turnover ₹166.87 Lakhs. Key results statem